加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.7601
−US$0.0099 · -1.29%
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
前收盘价
US$0.7601
−US$0.0099 · -1.29%
盘中时间采用ET。市场数据可能有所延迟。
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
日内区间
当前US$0.7601
52周区间
当前US$0.7601
盘中时间采用ET。市场数据可能有所延迟。
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
日内区间
当前US$0.7601
52周区间
当前US$0.7601
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | 38.9万 USD | — | — | — |
| 毛利 | — | −38.9万 USD | — | — | — |
| 研究与开发 | 1260.6万 USD | 2847.6万 USD | 1749.8万 USD | 2252.7万 USD | 1716.6万 USD |
| 销售、一般及管理费用 | 1396.9万 USD | 1355万 USD | 1165.9万 USD | 1211.3万 USD | 982万 USD |
| 营业费用 | 2657.5万 USD | 4163.7万 USD | 2915.7万 USD | 3464万 USD | 2698.6万 USD |
| 利息收入 | 52万 USD | 149.9万 USD | 111.5万 USD | 54.9万 USD | 1282 USD |
| 利息支出 | 20.7万 USD | 131.6万 USD | 144.9万 USD | 161.8万 USD | 128.2万 USD |
| 折旧和摊销 | 26.6万 USD | 38.9万 USD | 38.1万 USD | 63.8万 USD | 37.4万 USD |
| 营业利润 | −2657.5万 USD | −4202.6万 USD | −2915.7万 USD | −3464万 USD | −2698.6万 USD |
| 净利润 | −2626.2万 USD | −4184.3万 USD | −2949.1万 USD | −3570.9万 USD | −2830.2万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2025年4月9日 | 1:13 | — | — |
股票拆分 | 2021年6月28日 | 1:15 | — | — |
股票拆分 | 2018年12月10日 | 1:15 | — | — |
已生效 2025年4月9日
1:13
已生效 2021年6月28日
1:15
已生效 2018年12月10日
1:15
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
